StreetInsider.com News Articles

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:00:00 -0400

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment.

The RSUs will vest over 3

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:00:00 -0400

The RSUs will vest over 3

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:00:00 -0400

The RSUs will vest over 3

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:00:00 -0400

The RSUs will vest over 3

RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'

Wed, 17 Jun 2026 07:34:29 -0400

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $119.00 price target on Cytokinetics (NASDAQ: CYTK).

The analyst commented: "While Confirming A Competitive Threat, We Hope Moving Past '7500 Data Can Allow Shares To Rebound; We think heading into the readout, there was a significant amount of investors pair trading the names (and we think biased long CYTK). Given what we think was a muted reaction to ACACIA (just +16% which by June had faded further), we think the EWTX data was being perceived as an overhang on shares. Additionally, there was almost no appreciation of the positive early launch

RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'

Wed, 17 Jun 2026 07:34:29 -0400

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $119.00 price target on Cytokinetics (NASDAQ: CYTK).

Form 4 CYTOKINETICS INC For: Jun 15 Filed by: Blum Robert I

Mon, 15 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260615/26648039.html

Form 4 CYTOKINETICS INC For: Jun 15 Filed by: Blum Robert I

Mon, 15 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260615/26648039.html

Form 4 CYTOKINETICS INC For: Jun 09 Filed by: Malik Fady Ibraham

Tue, 09 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260609/26624945.html

Form 4 CYTOKINETICS INC For: Jun 09 Filed by: Malik Fady Ibraham

Tue, 09 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260609/26624945.html

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Mon, 08 Jun 2026 07:30:00 -0400

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values

Deadline for Applications is August 3, 2026

SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support equitable healthcare initiatives for cardiovascular disease, science education and certain essential services for local and at-risk communities.

“At Cytokinetics, our commitment to the communities around us is as fundamental to our

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Mon, 08 Jun 2026 07:30:00 -0400

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values

Deadline for Applications is August 3, 2026

“At Cytokinetics, our commitment to the communities around us is as fundamental to our

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Mon, 08 Jun 2026 07:30:00 -0400

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values

Deadline for Applications is August 3, 2026

“At Cytokinetics, our commitment to the communities around us is as fundamental to our

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Mon, 08 Jun 2026 07:30:00 -0400

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values

Deadline for Applications is August 3, 2026

“At Cytokinetics, our commitment to the communities around us is as fundamental to our

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26585514.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26585514.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Callos Andrew

Mon, 01 Jun 2026 18:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26585509.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: Callos Andrew

Mon, 01 Jun 2026 18:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26585509.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: PARSHALL B LYNNE

Mon, 01 Jun 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260601/26585505.html

Form 4 CYTOKINETICS INC For: Jun 01 Filed by: PARSHALL B LYNNE

Mon, 01 Jun 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260601/26585505.html

Form 144 CYTOKINETICS INC Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26583914.html

Form 144 CYTOKINETICS INC Filed by: Kaye Edward M. MD

Mon, 01 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260601/26583914.html

Cytokinetics launches MYQORZO in Germany, first EU market

Mon, 01 Jun 2026 07:32:24 -0400

Cytokinetics (NASDAQ: CYTK) announced the commercial launch of MYQORZO (aficamten) in Germany for treating symptomatic obstructive hypertrophic cardiomyopathy in adults. The drug launch represents the first European market availability following European Commission approval in February 2026.

MYQORZO is a cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy. The drug received approval based on results from the SEQUOIA-HCM Phase 3 clinical trial.

In the 24-week study, patients treated with aficamten showed improved exercise capacity compared to placebo. Peak oxygen uptake increased by 1.76 mL/kg/min from baseline in the treatment group versus

Cytokinetics launches MYQORZO in Germany, first EU market

Mon, 01 Jun 2026 07:32:24 -0400

In the 24-week study, patients treated with aficamten showed improved exercise capacity compared to placebo. Peak oxygen uptake increased by 1.76 mL/kg/min from baseline in the treatment group versus

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Mon, 01 Jun 2026 07:30:00 -0400

European Launch Follows Strong U.S. Start

SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.

Marking the first of several planned European